Breakthrough CD40 Antibody Eliminates Aggressive Cancers in Phase I Trial
A new class of cancer drugs, dubbed 2141-V11, has shown promising results in a Phase I clinical trial. The enhanced CD40 agonist antibody, engineered to improve efficacy and limit side effects, was administered directly into tumors, resulting in significant tumor shrinkage and even complete remission in six out of 12 patients. According to the study’s … Read more